Market reactionShares fell 10% on Nov 5.
Atara developed tabelecleucel (tab-cel), an off-the-shelf T-cell therapy for a rare lymphoma after transplant; partner Pierre Fabre sells it in Europe, and it is not approved in the U.S.
Tab-cel treats EBV-positive lymphoma after organ or stem cell transplant and is approved in Europe. FDA's first complete response letter, in January 2025, concerned a third-party manufacturing site; its second, in January 2026, said the single-arm ALLELE trial was not adequate. After a Type A meeting, Pierre Fabre resubmitted with more patients and longer follow-up, and FDA set a March 31, 2027 decision date. Approval would pay Atara a $31 million milestone. Cash was $9.9 million at June 30, with going-concern doubt.
Thesis checklist
3 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: FDA approves tab-cel on resubmission
Does FDA approve tab-cel for EBV+ PTLD on the updated single-arm ALLELE data?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Tab-cel's third FDA review ends March 31, 2027, and Atara has little cash
Third shot at FDA approval with going-concern clock ticking: does ALLELE data survive a second regulatory reversal?
Type A Meeting with FDA on tabelecleucel CRL
EBVALLO BLA Complete Response Letter
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Blood cancers, Infectious diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
1 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.